

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ZELIRA THERAPEUTICS LIMITED
ABN	27 103 782 378

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Jason Peterson
Date of last notice	29 September 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	i. Celtic Capital Pty Ltd <The Celtic Capital A/C> (Director/Shareholder) ii. Celtic Capital Pte Ltd <Investment 1 A/C> (Director/Shareholder) iii. Wicklow Capital Pty Ltd <Tipperary A/C> (Director/Shareholder) iv. Sunset Capital Management Pty Ltd <Sunset Superfund> (Director/Shareholder) v. Celtic Capital Pty Ltd <Income A/C> (Director/Shareholder) vi. CPS Capital No 3 Pty Ltd (Director/Shareholder)
Date of change	17 November 2021
No. of securities held prior to change	i. 11,200,000 ordinary shares ii. 5,800,000 ordinary shares iii. 1,642,105 ordinary shares iv. 55,951,847 ordinary shares iv. 8,000,000 options (\$0.03125; 17/11/2021) v. 4,375,000 Class A performance rights v. 4,375,000 Class B performance rights vi. 1,875,000 Class A performance rights vi. 1,875,000 Class B performance rights
Class	Unquoted options (\$0.03125; 17/11/2021)
Number acquired	

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number disposed	8,000,000
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	N/A – expiry of options
No. of securities held after change	i. 11,200,000 ordinary shares ii. 5,800,000 ordinary shares iii. Nil ordinary shares iv. 1,642,105 ordinary shares v. 55,951,847 ordinary shares vi. 4,375,000 Class A performance rights vi. 4,375,000 Class B performance rights vii. 1,875,000 Class A performance rights vii. 1,875,000 Class B performance rights
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Expiry of options

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
--	----

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ZELIRA THERAPEUTICS LIMITED
ABN	27 103 782 378

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Harry Karelis
Date of last notice	23 December 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Gemelli Nominees Pty Ltd <Gemelli Family A/C> - Director/shareholder
Date of change	17 November 2021
No. of securities held prior to change	49,587,680 ordinary shares 6,000,000 (\$0.03125; 17/11/2021) 6,250,000 Class A performance rights 6,250,000 Class B performance rights
Class	Unquoted options (\$0.03125; 17/11/2021)
Number acquired	
Number disposed	6,000,000
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	N/A – expiry of options
No. of securities held after change	49,587,680 ordinary shares 6,250,000 Class A performance rights 6,250,000 Class B performance rights
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Expiry of options

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

+ See chapter 19 for defined terms.

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.